Search

Your search keyword '"Amsili, Shira"' showing total 15 results
Start Over Author "Amsili, Shira"
15 results on '"Amsili, Shira"'

1. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Author

Cendrowicz, Ewa, Jacob, Lisa, Greenwald, Shirley, Tamir, Ami, Pecker, Iris, Tabakman, Rinat, Ghantous, Lucy, Tamir, Liat, Kahn, Roy, Avichzer, Jasmine, Aronin, Alexandra, Amsili, Shira, Zorde-Khvalevsky, Elina, Gozlan, Yosi, Vlaming, Martijn, Huls, Gerwin, van Meerten, Tom, Dranitzki, Michal Elhalel, Foley-Comer, Adam, Pereg, Yaron, Peled, Amnon, Chajut, Ayelet, and Bremer, Edwin

Published
2022
Full Text
View/download PDF

3. Figure S7 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL

Author

Makdasi, Efi, primary, Amsili, Shira, primary, Aronin, Alexandra, primary, Prigozhina, Tatyana B., primary, Tzdaka, Kobi, primary, Gozlan, Yosi Meir, primary, Ben Gigi–Tamir, Liat, primary, Sagiv, Jitka Yehudith, primary, Shkedy, Fanny, primary, Shani, Noam, primary, Tykocinski, Mark L., primary, and Dranitzki Elhalel, Michal, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Methods from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL

Author

Makdasi, Efi, primary, Amsili, Shira, primary, Aronin, Alexandra, primary, Prigozhina, Tatyana B., primary, Tzdaka, Kobi, primary, Gozlan, Yosi Meir, primary, Ben Gigi–Tamir, Liat, primary, Sagiv, Jitka Yehudith, primary, Shkedy, Fanny, primary, Shani, Noam, primary, Tykocinski, Mark L., primary, and Dranitzki Elhalel, Michal, primary

Published
2023
Full Text
View/download PDF

5. Table S1, S2 from Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL

Author

Makdasi, Efi, primary, Amsili, Shira, primary, Aronin, Alexandra, primary, Prigozhina, Tatyana B., primary, Tzdaka, Kobi, primary, Gozlan, Yosi Meir, primary, Ben Gigi–Tamir, Liat, primary, Sagiv, Jitka Yehudith, primary, Shkedy, Fanny, primary, Shani, Noam, primary, Tykocinski, Mark L., primary, and Dranitzki Elhalel, Michal, primary

Published
2023
Full Text
View/download PDF

7. Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL

Author

Makdasi, Efi, primary, Amsili, Shira, additional, Aronin, Alexandra, additional, Prigozhina, Tatyana B., additional, Tzdaka, Kobi, additional, Gozlan, Yosi Meir, additional, Ben Gigi–Tamir, Liat, additional, Sagiv, Jitka Yehudith, additional, Shkedy, Fanny, additional, Shani, Noam, additional, Tykocinski, Mark L., additional, and Dranitzki Elhalel, Michal, additional

Published
2020
Full Text
View/download PDF

9. Abstract A076: DSP107—a novel SIRPα-4-1BBL dual signaling protein (DSP) for cancer immunotherapy

Author

Gozlan, Yosi M., primary, Hilgendorf, Susan, additional, Aronin, Alexandra, additional, Sagiv, Yehudith, additional, Ben-gigi-Tamir, Liat, additional, Amsili, Shira, additional, Tamir, Ami, additional, Pecker, Iris, additional, Greenwald, Shirley, additional, Chajut, Ayelet, additional, Foley-Comer, Adam, additional, Pereg, Yaron, additional, Peled, Amnon, additional, Dranitzki-Elhalel, Michal, additional, and Bremer, Edwin, additional

Published
2019
Full Text
View/download PDF

15. CTLA4-FasL, the Hexameric Targeted FasL Fusion Protein, As Potential Novel Treatment for DLBCL

Author

Aronin, Alexandra, Ben Gigi-Tamir, Liat, Makdasi, Efi, Amsili, Shira, Ben David, Shlomi, Avraham, Ortal, Sagiv, Yehudith Jitka, Gozlan, Yosi Meir, Shani, Noam, and Dranitzki Elhalel, Michal

Abstract

The bi-functional drug CTLA4-FasL (KAHR-102) is a fusion protein composed of the extracellular domains of CTLA4 and FasL. It naturally forms a stable homo-hexamer capable of targeting two different cellular receptors; the CTLA4 domains target B7 receptors (CD80 and CD86) on cells bearing these receptors, while the FasL domains target functional Fas-receptors (CD95) to induce apoptosis. Although CTLA4-FasL can induce apoptosis in all cells expressing functional Fas receptors, it is at least 100 times more potent on cells expressing both B7 and functional Fas receptors. The higher efficacy in cells expressing both receptors is adjoined by robust activation of pro-apoptotic intracellular pathways in conjunction to abrogation of anti-apoptotic ones. This unique combined activity cannot be detected in cells bearing just Fas receptors and can be blocked by preventing the binding of the protein to CD80 and CD86. Both B7 and functional Fas receptors are expressed on lymphoma cells, mainly of the B cell lineage, making them exceptionally sensitive to the CTLA4-FasL apoptotic effect.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results